- Home
- QNBC vs ACIU Comparison
QNBC vs ACIU Comparison
Compare QNBC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QNBC | ACIU |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.3M | 247.6M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | QNBC | ACIU |
|---|---|---|
| Price | $45.45 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 8.2K | ★ 128.3K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.15 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $34.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.75 | $2.10 |
| 52 Week High | $45.90 | $4.00 |
Technical Indicators
Market Signals| Indicator | QNBC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $45.90 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 73.04 | 0.00 |
Price Performance
Historical ComparisonAbout QNBC QNB Corp. Common Stock
QNB Corp is a bank holding company based in the United States. It operates through its wholly-owned subsidiary, which engages in the general commercial banking business and offers a full range of banking services to its customers. Its business activities involve attracting deposits and using funds in making commercial loans, residential mortgage loans, consumer loans, and purchasing investment securities. The loan portfolio includes commercial loans, such as commercial and industrial, construction, and loans secured by commercial real estate and residential real estate, and retail loans, including home equity loans and lines, and consumer loans. It generates revenue from net interest income.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.